AstraZeneca PLC (AZN)vsSionna Therapeutics, Inc. Common Stock (SION)
AZN
AstraZeneca PLC
$188.41
+1.47%
HEALTHCARE · Cap: $284.30B
SION
Sionna Therapeutics, Inc. Common Stock
$42.77
-6.38%
HEALTHCARE · Cap: $1.93B
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SION
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$188.41
$6.16 discount
Intrinsic value data unavailable for SION.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SION
The strongest argument for SION centers on Debt/Equity, Altman Z-Score.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SION
The primary concerns for SION are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while SION is a value play — different risk/reward profiles.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 23/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sionna Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Sionna Therapeutics, Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge therapies for neurodegenerative disorders, specifically targeting conditions such as Alzheimer's and Parkinson's diseases characterized by protein misfolding. With a strong pipeline bolstered by proprietary technologies, the company is positioned to meet significant unmet medical needs in this critical therapeutic area. Sionna’s strategic collaborations and a steadfast commitment to research and development underscore its status as a key player in the biopharmaceutical landscape, aiming to improve patient outcomes and quality of life through innovative neurological solutions.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?